Indication
- Ilumya is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Last updated on 2/4/2021| Document Title | Year | Source |
| A systematic literature review and bucher indirect comparison: tildrakizumab versus guselkumab. | 2020 | Journal of Health Economics and Outcomes Research |
| Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis. | 2020 | Journal of the European Academy of Dermatology and Venereology |
| Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple‐treatments meta‐analysis. | 2020 | Journal of the German Society of Dermatology |
| Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: A systematic review and network meta-analysis of randomized controlled trials. | 2019 | Journal of Immunology Research |
| A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. | 2018 | The Journal of Dermatological Treatment |
